Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2005

View Archived Issues

Rylomine induces analgesic effects in patients with postsurgical orthopedic pain

Celldex Therapeutics acquires Lorantis and assets of Alteris Therapeutics

OGX-011 begins new phase II study in prostate cancer

GPI-0100 adjuvant licensed by Hawaii Biotech

Osiris to begin phase II study of Prochymal for severe GVHD

Arrowhead Research accelerates investment in Insert Therapeutics

Trexima NDA accepted for review

IND filing for MEDI-545 for lupus

RTA-401 cleared for clinical testing

KP-1461 begins phase Ib study for HIV

Talabostat begins phase III for metastatic NSCLC

CHIR-12.12 enters phase I study for multiple myeloma

Inspire completes studies prior to end-of-phase II meeting

Mack and Transport enter agreement for cold sores device/drug product

Aerie closes Series A financing

Phase III program under way for Memryte implant

Benefits of rHuPH20 for cerebral brain ischemia and enhanced pharmacokinetics

M-475271 antitumor effects via inhibition of angiogenesis

Targeting CIDS for CNS injury: a new avenue for therapeutic investigation

New PDE inhibitors disclosed by Altana

Janssen patent claims new opioid receptor agonists for pain

Novel anti-HIV agents reported in recent patent literature

LY-456236 produces anticonvulsant effects in preclinical testing

New data on the metabolic effects of orexin A

Oral insulin prevents postprandial glucose excursions in patients with type 1 diabetes

Pioglitazone improves cardiovascular outcome in patients with type 2 diabetes

Update on the antibacterial efficacy of tigecycline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...